We are monitoring the impact of COVID-19 on North America Narcolepsy Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 6661
Share on
Share on

North America Narcolepsy Drugs Market Research Report – Segmented By Type, Indication and Country (the United States, Canada and Rest of North America) – Industry Size, Share, Trends and Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 6661
Pages: 145

North America Narcolepsy Drugs Market Size (2021 to 2026)

The size of the Narcolepsy Drugs Market in North America is estimated to grow at a promising rate from 2021 to 2026. Narcolepsy is a neurological disorder that decreases the ability to regulate sleep cycles.

Y-O-Y growth in the incidence of narcolepsy and other disorders associated with sleep and fulfillment of reimbursement schemes relevant to narcolepsy and bringing out awareness programs and services regarding the importance of early narcolepsy diagnosis are to propel the growth. Market key players, research and development activities headed by various academic and research institutes, and escalating demand for rare diseases medication from biopharmaceutical and biotechnology companies are likely to add fuel to the market. Around 135,000 to 200,000 citizens of the U.S. are diagnosed with narcolepsy, according to the National Institute of Neurological Disorders and Stroke in 2018. 1 in 2,000 people in the United States was diagnosed with narcolepsy in 2012. Growth in alcohol consumption, tobacco, smoking destroying the sleeping patterns and lifestyle changes in young singles, and augmenting stress levels are some factors stimulating the narcolepsy drug market in North America.

Less awareness about narcolepsy and significantly less per head healthcare expenses in the regional limits of middle and low-income countries is predicted to hinder the market growth during North America.

This research report on North America Narcolepsy Drugs Market has been segmented & sub-segmented into the following categories:

  • By Type: Central Nervous System Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, and Others
  • By Indication: Daytime Extreme Sleepiness, Cataplexia, and Others
  • By Country: The United States, Canada, and Rest of North America

Regional Analysis:

North America is ruling the market and is accounted to hold remarkable growth in the global narcolepsy drugs market during the forecast period. This region is projected to maintain its dominance because having consciousness amid people, availability of outstanding healthcare amenities, and rising citizens in this region are predicted to stimulate market growth.

The USA holds a significant share in the market due to market leaders' presence and the presence of a stellar healthcare system. The United States is also the fastest-growing region due to increasing disposable income, growing awareness, and rising adoption rates. The United States is governing the Narcolepsy drugs market in North America due to different regulatory bodies guiding the production of pharmaceutical products. Governing bodies like US FDA motivates and upgrades the enhancement of treatment for rare diseases. North American countries' U.S. and Canada have favored the usage of generic drugs leading to an expanding number of international players to access the markets. Moreover, expanded research among the pharmaceutical and biotechnology industries is expected further to strengthen the market growth during the estimated period. An increase in the obese population, a firmly-developed healthcare domain, and substantial healthcare expenses are to surge the market. The existence of developed economies such as U.S and Canada market players like Mylan N.V., and Ligand Pharmaceuticals, and others in the regional limits boost the market growth of the Narcolepsy drugs market.

Some of the key players dominating the North America Narcolepsy Drugs market include Ligand Pharmaceuticals, Addrenex Pharmaceuticals, Shire Plc, Teva Pharmaceutical Industries Ltd., Arena Pharmaceuticals, Jazz Pharmaceuticals Plc, Bioprojet, and Graymark Healthcare, Inc.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Type                              

                                5.1.1 Introduction           

                                5.1.2 Central Nervous System Stimulants             

                                5.1.3 Tricyclic Antidepressants   

                                5.1.4 Sodium Oxybate   

                                5.1.5 Selective Serotonin Reuptake Inhibitor      

                                5.1.6 Others      

                                5.1.7  Y-o-Y Growth Analysis, By Type    

                                5.1.8  Market Attractiveness Analysis, By Type  

                                5.1.9  Market Share Analysis, By Type    

                5.2 Indication                    

                                5.2.1 Introduction           

                                5.2.2 Daytime Extreme Sleepiness          

                                5.2.3 Cataplexia               

                                5.2.4 Others      

                                5.2.5 Y-o-Y Growth Analysis, By Indication           

                                5.2.6 Market Attractiveness Analysis, By Indication         

                                5.2.7 Market Share Analysis, By Indication           

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Type

                                                6.1.3.3 By Indication

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Type

                                                6.1.4.3 By Indication

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Type

                                                6.1.5.3 By Indication

                6.2 United States                            

                6.3 Canada                         

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Ligand Pharmaceuticals                         

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Addrenex Pharmaceuticals                  

                8.3 Shire Plc                       

                8.4 Teva Pharmaceutical Industries Ltd.                

                8.5 Arena Pharmaceuticals                          

                8.6 Jazz Pharmaceuticals Plc                       

                8.7 Bioprojet                     

                8.8 Graymark Healthcare, Inc                     

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms by indication with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Narcolepsy Drugs Market, By Type, From 2021 to 2026 (USD Million)
  2. North America Central Nervous System Stimulants Market, By Region, From 2021 to 2026 (USD Million)
  3. North America Tricyclic Antidepressants Market, By Region, From 2021 to 2026 (USD Million)
  4. North America Sodium Oxybate Market, By Region, From 2021 to 2026 (USD Million)
  5. North America Selective Serotonin Reuptake Inhibitor Market, By Region, From 2021 to 2026 (USD Million)
  6. North America Others Market, By Region, From 2021 to 2026 (USD Million)
  7. North America Narcolepsy Drugs Market, By Indication, From 2021 to 2026 (USD Million)
  8. North America Daytime Extreme Sleepiness Market, By Region, From 2021 to 2026 (USD Million)
  9. North America Cataplexia Market, By Region, From 2021 to 2026 (USD Million)
  10. North America Others Market, By Region, From 2021 to 2026 (USD Million)
  11. United States Narcolepsy Drugs Market, By Type, From 2021 to 2026 (USD Million)
  12. United States Narcolepsy Drugs Market, By Indication, From 2021 to 2026 (USD Million)
  13. Canada Narcolepsy Drugs Market, By Type, From 2021 to 2026 (USD Million)
  14. Canada Narcolepsy Drugs Market, By Indication, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample